TY - JOUR
T1 - Endophenotypic Variations of Atopic Dermatitis by Age, Race, and Ethnicity
AU - Nomura, Takashi
AU - Wu, Jianni
AU - Kabashima, Kenji
AU - Guttman-Yassky, Emma
N1 - Funding Information:
Conflicts of interest: E. Guttman-Yassky is an employee of Mount Sinai and has received research funds (grants paid to the institution) from Abbvie, Celgene, Eli Lilly, Janssen, Medimmune/AstraZeneca, Novartis, Pfizer, Regeneron, Vitae, Glenmark, Galderma, Asana, Innovaderm, Dermira, and UCB and is also a consultant for Sanofi Aventis, Regeneron, Stiefel/GlaxoSmithKline, MedImmune, Celgene, Anacor, AnaptysBio, Dermira, Galderma, Glenmark, Novartis, Pfizer, Vitae, Leo Pharma, Abbvie, Eli Lilly, Kyowa, Mitsubishi Tanabe, Asana Biosciences, and Promius. K. Kabashima is an employee of Kyoto University and is a consultant for Japan Tobacco, LEO Pharma, Maruho, Mitsubishi Tanabe, Ono, Procter & Gamble, Sanofi, Taiho, and Torii. T. Nomura is an employee of Kyoto University. J. Wu declares no relevant conflicts of interest. The authors received no funding for this study.
Publisher Copyright:
© 2020 American Academy of Allergy, Asthma & Immunology
PY - 2020/6
Y1 - 2020/6
N2 - Atopic dermatitis (AD) is a heterogeneous disease with unique clinical manifestations across age groups and race/ethnicities. Characteristic molecular mechanisms, known as endotypes, including IgE level, status of epidermal barrier genes, and differential cytokine axes activation in the background of TH2 upregulation, are also implicated. In adults, the TH22, TH17, and TH1 pathways are involved, and a weakened epidermal barrier is characteristic. In contrast, pediatric patients exhibit less TH1 activation, and defects in epidermal lipid metabolism contribute to their barrier defect. European American patients are characterized by higher differential TH2/TH22 activation, lower expression of the TH1/TH17 axes, and suppression of filaggrin (FLG) and loricrin gene expressions. Asian patients have accentuated polarity of the TH22/TH17 pathways, and also exhibit epidermal barrier defects despite relative maintenance of FLG and loricrin expression. African American patients do not exhibit FLG mutations and have distinct attenuation of TH17/TH1 axes activation. Dissecting the molecular basis of AD endotypes has provided an important framework upon which targeted therapeutics are being developed. An increased understanding of these subtypes and the alteration of biomarkers that correlate with disease can ultimately push AD treatment in an era of personalized medicine.
AB - Atopic dermatitis (AD) is a heterogeneous disease with unique clinical manifestations across age groups and race/ethnicities. Characteristic molecular mechanisms, known as endotypes, including IgE level, status of epidermal barrier genes, and differential cytokine axes activation in the background of TH2 upregulation, are also implicated. In adults, the TH22, TH17, and TH1 pathways are involved, and a weakened epidermal barrier is characteristic. In contrast, pediatric patients exhibit less TH1 activation, and defects in epidermal lipid metabolism contribute to their barrier defect. European American patients are characterized by higher differential TH2/TH22 activation, lower expression of the TH1/TH17 axes, and suppression of filaggrin (FLG) and loricrin gene expressions. Asian patients have accentuated polarity of the TH22/TH17 pathways, and also exhibit epidermal barrier defects despite relative maintenance of FLG and loricrin expression. African American patients do not exhibit FLG mutations and have distinct attenuation of TH17/TH1 axes activation. Dissecting the molecular basis of AD endotypes has provided an important framework upon which targeted therapeutics are being developed. An increased understanding of these subtypes and the alteration of biomarkers that correlate with disease can ultimately push AD treatment in an era of personalized medicine.
KW - Age
KW - Atopic dermatitis
KW - Dupilumab
KW - Endotypes
KW - Ethnicity
KW - Genetics
KW - Phenotypes
KW - Precision medicine
KW - Race
UR - http://www.scopus.com/inward/record.url?scp=85085651517&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2020.02.022
DO - 10.1016/j.jaip.2020.02.022
M3 - Article
C2 - 32499033
AN - SCOPUS:85085651517
SN - 2213-2198
VL - 8
SP - 1840
EP - 1852
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 6
ER -